Retinal Ischemia Treatment by Oxygen Nanobubbles

氧纳米气泡治疗视网膜缺血

基本信息

批准号：
10723843
负责人：
Joseph MK Irudayaraj
金额：
$ 44.34万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-30 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10723843
关键词：
Address Adverse reactions Aftercare Animal Model Autoimmune Responses Automobile Driving Bilateral Biochemical Biochemical Markers Biochemical Pathway Biodistribution Biological Blindness Blood Vessels Blood flow Cell Death Cell Line Cells Cellulose Characteristics Data Development Dextrans Diabetic Retinopathy Disease Electroretinography Event Experimental Models Eye Family suidae Formulation Goals Histology Hour Human Hyperbaric Oxygenation Hypoxia Imaging technology Impairment Inflammation Injectable Injury Ischemia Measures Mediator Metabolic Metabolism Modality Modeling Morphology Multimodal Imaging Neurons Nutrient Optical Coherence Tomography Outcome Oxygen Oxygen Therapy Care Pathogenesis Patients Play Predisposition Property Rattus Reactive Oxygen Species Recovery Research Retina Retinal Vascular Occlusion Rodent Role Safety Series Statistical Data Interpretation Structure Symptoms Technology Testing Therapeutic Therapeutic Effect Therapeutic Intervention Thick Time Tissues Treatment Effectiveness Treatment outcome Vascular blood supply Vision Visual Visual impairment artery occlusion biomaterial compatibility cell injury chemical property clinical implementation clinical practice effective therapy efficacious treatment efficacy evaluation experience imaging system improved innovation instrument intravitreal injection nanobubble nanocarrier novel novel therapeutic intervention physical property preservation prevent retina circulation retinal imaging retinal ischemia standard of care therapeutic development translational barrier treatment effect visual processing

项目摘要

Abstract The retinal tissue is highly susceptible to inadequate oxygenation due to its high metabolic activity. Indeed, it is commonly accepted that retinal hypoxia plays a central role in the events leading to neuronal cell damage and death due to ischemia and implicated in visual impairments due to retinal vascular occlusions and diabetic retinopathy. Previous studies have investigated the use of hyperbaric oxygen treatment for retinal ischemia. However, the effectiveness of this treatment to supply adequate oxygen to the inner retina is limited and a standard of care does not exist. We address an unmet need for the development of therapeutic interventions to oxygenate the retinal tissue and prevent vision loss from an ischemic insult. We propose the concept of oxygenation of the inner retina with oxygen nanobubbles (ONBs) that can release oxygen over an extended period of time as a novel treatment modality for retinal ischemia. Our aims are to: develop a consistent formulation for the synthesis of ONBs and evaluate its physical and biochemical properties; identify the optimum time for administration of ONBs treatment to improve ischemia-induced impairments of retinal oxygen metrics and visual function; and determine the efficacy of ONBs treatment based on a series of comprehensive outcomes, namely, retinal oxygen metrics, visual function, retinal thickness, and biochemical pathways. We expect our findings will serve as strong preliminary evidence of an innovative therapeutic intervention to mitigate ischemic insult, preserve the retinal tissue from injury, and prevent vision loss.

抽象的视网膜组织由于其高代谢而极易受到氧合不足的影响活动。事实上，人们普遍认为视网膜缺氧在这些事件中起着核心作用导致神经细胞因缺血而损伤和死亡，并与视力障碍有关由于视网膜血管闭塞和糖尿病视网膜病变。之前的研究已经调查过使用高压氧治疗视网膜缺血。然而，这种做法的有效性为内视网膜提供足够氧气的治疗是有限的，护理标准并不不存在。我们解决了开发治疗干预措施的未满足的需求使视网膜组织充氧并防止缺血性损伤导致视力丧失。我们建议使用可以释放的氧纳米气泡（ONB）对视网膜内部进行氧合的概念长时间吸氧是治疗视网膜缺血的一种新方法。我们的目标是：开发一致的 ONB 合成配方并评估其物理和生化特性；确定 ONB 给药的最佳时间改善缺血引起的视网膜氧指标和视力损伤的治疗功能;并根据一系列综合指标确定ONBs治疗的疗效结果，即视网膜氧指标、视功能、视网膜厚度和生化指标途径。我们期望我们的发现将成为创新的强有力的初步证据治疗干预以减轻缺血性损伤，保护视网膜组织免受损伤，以及防止视力丧失。